Cardiovascular Risk Factor Burden in the United Arab Emirates (UAE): The Africa Middle East (AfME) Cardiovascular Epidemiological (ACE) Study Sub-analysis
International Cardiovascular Forum Journal · 2017
DOI: 10.17987/icfj.v11i0.414 ↗Abstract
Background: The Africa Middle East (AfME) Cardiovascular Epidemiological (ACE) study demonstrated that cardiovascular risk factors are highly prevalent among relatively young adult outpatients attending general practice clinics across AfME regions.
Objective: Based on the broader AfME estimates from the ACE Study, this sub-analysis evaluated the prevalence of cardiovascular risk factors in the United Arab Emirates (UAE), particularly in rural and urban cohorts attending general practice clinics.
Methods: Data from the cross-sectional ACE study were used: stable, adult outpatients attending general practice clinics in the UAE. Prevalence of six CV risk factors were analyzed: hypertension, diabetes, dyslipidemia, obesity, smoking, abdominal obesity. Rural populations were defined as living >50km from urban centers, or lack of transportation.
Results: In this cohort of 495 patients (aged 45.1 years; 49.8% female) from the UAE, a high prevalence of abdominal obesity (71.5%) and dyslipidemia (74.0%) was found. Nearly half of patients had hypertension (43.0%) and one-third diabetes (32.4%). Nearly all outpatients (92.9%) had ≥1 modifiable risk factor (74.9% had ≥1, 59.7% had ≥3). Observations were similar by gender, and across urban and rural centers. Many outpatients with pre-existing hypertension or dyslipidemia did not meet recognized blood pressure or low-density lipoprotein cholesterol goals.
Conclusions: Cardiovascular risk factors are prevalent among relatively young adult, clinically stable outpatients attending outpatient clinics across the UAE. These findings support targeted screening of outpatients visiting a general practitioner, which may provide opportunity for early discovery and ongoing management of risk factors, including recommending lifestyle changes. The ACE trial is registered under NCT01243138.
EUVIMED